The muscarinic M1/M4receptor agonist xanomeline exhibits antipsychotic-like activity in cebus apella monkeys

Neuropsychopharmacology

Volumn 28, Issue 6, 2003, Pages 1168-1175

  Andersen, Maibritt B ^a   Fink Jensen, Anders ^b   Peacock, Linda ^a   Gerlach, Jes ^a   Bymaster, Frank ^c   Lundbæk, Jens August ^a   Werge, Thomas ^a  

^a Sct Hans Hospital   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Amphetamine; Apomorphine; Cebus; Monkey; Muscarinic agonist; Xanomeline

Indexed keywords

AMPHETAMINE; APOMORPHINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; PYRIDINE DERIVATIVE; THIADIAZOLE DERIVATIVE; XANOMELINE;

ANIMAL; ARTICLE; CEBIDAE; MALE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CEBUS; MALE; MUSCARINIC AGONISTS; PSYCHOTIC DISORDERS; PYRIDINES; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC; THIADIAZOLES;

EID: 0042844763     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300151     Document Type: Article

References (52)

1. ArntJ(1982). Pharmacological specificity of conditioned avoid-ance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade.ActaPharmacolToxicol51: 321-329.
2. ArntJ, ChristensenAV, HyttelJ, LarsenJJ, SvendsenO(1982). Effects of putative dopamine autoreceptor agonists in pharma-cological models related to dopaminergic and neurolepticactivity.Eur J Pharmacol86: 185-198.
3. ArvanitisLA, MillerBG(1997). Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophre-nia: a comparison with haloperidol and placebo. The SeroquelTrial 13 Study Group.Biol Psychiatry42: 233-246.
4. AubertI, GhorayebI, NormandE, BlochB(2000). Phenotypical characterization of the neurons expressing the D1 and D2 dopaminereceptors in the monkey striatum.J Comp Neurol418: 22-32.
5. BartolomeoAC, MorrisH, BuccafuscoJJ, KilleN, Rosenzweig-LipsonS, Husbands MGet al(2000). The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.J PharmacolExpTher292: 584-596.
6. BernardV, NormandE, BlochB(1992). Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes.J Neurosci12: 3591-3600.
7. BodickNC, OffenWW, LeveyAI, CutlerNR, GauthierSG, Satlin Aet al(1997). Effects of xanomeline, a selective muscarinicreceptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.Arch Neurol54: 465-473.
8. BraffDL, GrillonC, GeyerMA(1992). Gating and habituation of the startle reflex in schizophrenic patients.Arch Gen Psychiatry49: 206-215.
9. BraffD, StoneC, CallawayE, GeyerM, GlickI, BaliL(1978). Prestimulus effects on human startle reflex in normals andschizophrenics.Psychophysiology15: 339-343.
10. BymasterFP, ShannonHE, RasmussenK, DeLappNW, MitchCH, Ward JSet al(1998). Unexpected antipsychotic-like activity withthe muscarinic receptor ligand (5R, 6R)6-(3-propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane.Eur J Pharmacol356:109-119.
11. BymasterFP, WhitesittCA, ShannonHE, DeLappNW, WardJS, Calligaro DOet al(1997). Xanomeline: a selective muscarinic agonistfor the treatment of Alzheimers disease.Drug Dev Res40: 158-177.
12. BymasterFP, WongDT, MitchCH, WardJS, Calligaro DO, Schoepp DD etal(1994). Neurochemical effects of the M1muscarinic agonist xanomeline (LY246708/NNC11-0232).JPharmacolExpTher269: 282-289.
13. CadenheadKS, SwerdlowNR, ShaferKM, DiazM, BraffD(2000).Modulation of the startle response and startle laterality inrelatives of schizophrenic patients and in subjects withschizotypal personality disorder: evidence of inhibitory deficits.Am J Psychiatry157: 1660-1668.
14. CummingsJL(2000). Cholinesterase inhibitors: a new class of psychotropic compounds.Am J Psychiatry157: 4-15.
15. DiChiaraG, MorelliM, ConsoloS(1994). Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions.Trends Neurosci17: 228-233.
16. DoodyRS, GeldmacherDS, GordonB, PerdomoCA, PrattRD(2001).Open-label, multicenter, phase 3 extension study of thesafety and efficacy of donepezil in patients with Alzheimerdisease.Arch Neurol58: 427-433.
17. EglenRM, ChoppinA, WatsonN(2001). Therapeutic opportu-nities from muscarinic receptor research.Trends PharmacolSci22: 409-414.
18. FardeL, SuharaT, HalldinC, NybackH, NakashimaY, Swahn CGet al(1996). PET study of the M1-agonists [11C]xanomelineand [11C]butylthio-TZTP in monkey and man.Dementia7:187-195.
19. FelderCC, BymasterFP, WardJ, DeLappN(2000). Therapeutic opportunities for muscarinic receptors in the central nervoussystem.J Med Chem43: 4333-4353.
20. Fink-JensenA, KristensenP, ShannonHE, CalligaroDO, DeLappNW, Whitesitt Cet al(1998). Muscarinic agonists exhibitfunctional dopamine antagonism in unilaterally 6-OHDAlesioned rats.Neuroreport9: 3481-3486.
21. FittenLJ, OrtizF, SiembiedaDW, O’NeillJ, HalgrenE, FisherA(1999). Reduction of motoric agitation and restlessness byAF102B and tacrine in the macaque.J Neuropsychiatry ClinNeurosci11: 79-85.
22. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI (1995). Differential regulation of molecular subtypes of muscarinic receptors inAlzheimer’s disease.J Neurochem64: 1888-1891.
23. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001). Hyperactivity, elevated dopaminergictransmission, and response to amphetamine in M1 muscarinicacetylcholine receptor-deficient mice.ProcNatlAcadSci USA98:15312-15317.
24. Gerlach J, Bjorndal N, Christensson E (1984). Methylphenidate, apomorphine, THIP, and diazepam in monkeys: dopamine-GABA behavior related to psychoses and tardive dyskinesia.Psychopharmacology82: 131-134.
25. Gerlach J, Casey DE (1990). Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.ProgNeuropsy-chopharmacolBiol Psychiatry14: 103-112.
26. Glenthoj BY, Mackeprang T, Fagerlund B, Hemmingsen RP (2001). Effects of antipsychotic treatment on prepulse inhibition of thestartle response and cognition in first-episode drug-nalveschizophrenic patients.Schizophr Res49: 133-133(Abstract).
27. GomezaJ, ZhangL, KostenisE, FelderC, BymasterF, Brodkin Jet al(1999). Enhancement of D1 dopamine receptor-mediatedlocomotor stimulation in M(4) muscarinic acetylcholinereceptor knockout mice.ProcNatlAcadSci USA96: 10483-10488.
28. Harries MH, SamsonNA, CiliaJ, HunterAJ(1998). The profile of sabcomeline (SB-202026), a functionally selective M1 receptorpartial agonist, in the marmoset.Br J Pharmacol124: 409-415.
29. Hartvig P, Nordberg A, Torstenson R, Sjoberg P, Fasth KJ, Langstrom B (2002). Interaction of a muscarinic cholinergic agonist on acetylcholine and dopamine receptors in the monkey brain studied with positron emission tomography.DementGeriatr CognDisord13: 199-204.
30. HulmeEC, BirdsalNJM, BuckleyNJ(1990).Muscarinic receptor subtypes.Ann Rev PharmacolToxicol30: 633-673.
31. KaneJM, FreemanHL(1994). Towards more effective antipsycho-tic treatment.Br J Psychiatry35(Suppl): 22-31.
32. LeveyAI, KittCA, SimondsWF, PriceDL, BrannMR(1991). Identification and localization of muscarinic acetylcholinereceptor proteins in brain with subtype-specific antibodies.JNeurosci11: 3218-3226.
33. LublinH, GerlachJ, PeacockL(1992). Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.ClinNeuropharmacol15: 448-458.
34. MeltzerHY, McGurkSR(1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizo-phrenia.Schizophr Bull25: 233-255.
35. MeltzerHY, ParkS, KesslerR(1999). Cognition, schizophrenia, and the atypical antipsychotic drugs.ProcNatlAcadSci USA96:13591-13593.
36. ParwaniA, DuncanEJ, BartlettE, MadonickSH, EfferenTR, Rajan Ret al(2000). Impaired prepulse inhibition of acoustic startle inschizophrenia.Biol Psychiatry47: 662-669.
37. PeacockL, GerlachJ(1993). Effects of several partial dopamine D2 receptor agonists inCebusapellamonkeys previously treatedwith haloperidol.Eur J Pharmacol237: 329-340.
38. PeacockL, GerlachJ(1999). New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.Psychopharmacology144: 189-197.
39. Peacock L, Hansen L, Morkeberg F, Gerlach J (1999). Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2antagonist treatment inCebusapellamonkeys: antiamphetamineeffects and extrapyramidal side effects.Neuropsychopharmacol-ogy20: 35-43.
40. PeacockL, LublinH, GerlachJ(1990). The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawnfrom long-term neuroleptic treatment.Eur J Pharmacol186: 49-59.
41. PerryKW, NisenbaumLK, GeorgeCA, ShannonHE, FelderCC, BymasterFP(2001). The muscarinic agonist xanomelineincreases monoamine release and immediate early gene expression in the rat prefrontal cortex.Biol Psychiatry49: 716-725.
42. PfeifferCC, JenneyEH(1957).The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinicstimulation of the brain.Ann NY AcadSci66: 753-764.
43. SchwarzRD, CallahanMJ, CoughenourLL, DickersonMR, KinsoraJJ, Lipinski WJet al(1999). Milameline (CI-979/RU35926): amuscarinic receptor agonist with cognition-a ctivating properties: biochemical andin vivocharacterization.J PharmacolExpTher291: 812-822.
44. Seeman P, Kapur S (2000). Schizophrenia: more dopamine, more D2 receptors.ProcNatl AcadSci USA97: 7673-7675.
45. Seeman P, Lee T, Chau-Wong M, Wong K (1976).Antipsychotic drug doses and neuroleptic/dopamine receptors.Nature261:717-719.
46. SeemanP, VanTH(1994). Dopamine receptor pharmacology.Trends PharmacolSci15: 264-270.
47. ShannonHE, HartJC, BymasterFP, CalligaroDO, DeLappNW, Mitch CHet al(1999). Muscarinic receptor agonists, likedopamine receptor antagonist antipsychotics, inhibit condi-tioned avoidance response in rats.J PharmacolExpTher290:901-907.
48. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MDet al(2000). Xanomeline, an M(1)/M(4) preferringmuscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res42: 249-259.
49. ShekharA, PotterWZ, LienemannJ, SundbladK, LightfootJ, Herrera Jet al(2001). Efficacy of xanomeline, a selective muscarinic agonist, in treating schizophrenia: a double-blind, placebo controlled study. 40th Annual Meeting, Hawaii, December 9–13, 2001.
50. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB et al (2001). The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299: 782–792.
51. WeinerDM, LeveyAI, BrannMR(1990). Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basalganglia.ProcNatlAcadSci87: 7050-7054.
52. WhiteKE, CummingsJL(1996). Schizophrenia and Alzheimer’s disease: clinical and pathophysiologic analogies.ComprPsy-chiatry37: 188-195.